Delivery Order SPE2DB24D1205-SPE2DB24FCREP
Award Date 5/10/24
Potential Completion Date 6/3/24
Potential Value $23K
Federal Agency
Ultimate Awardee
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 mg/10 mL vials. The delivery order, valued at $23,118.08, has an ultimate completion date of April 22, 2024. This award is part of a larger indefinite delivery contract (IDC) awarded by DLA to Amerisourcebergen Drug Corp, with a potential value of $999,999,999.00 and a period of performance through...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4564133145 OCREVUS 300 MG/10 ML VIAL 10ML pharmaceutical products. The contract has a ceiling value of $46,236.16 and runs through April 22, 2024. This delivery order falls under an indefinite delivery contract (IDC) held by AmerisourceBergen Drug Corp with a potential value of up to $999,999,999.00 and a...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corp's Corporate Office Division, a major pharmaceutical distributor, for the supply of 4564617533 ! OCREVUS 300 MG/10 ML VIAL 10ML. The delivery order, valued at $23,118.08, is a firm fixed price contract with a completion date of June 6, 2024. This order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999.00 and...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product OCREVUS 300 MG/10 ML VIAL 10ML. The order has a potential value of $23,118.08 and a completion date of March 12, 2024. Amerisourcebergen Drug Corp is the prime contractor on this delivery order, which is issued under a larger indefinite delivery contract (IDC) the company...
- The Defense Logistics Agency (DLA) awarded a delivery order contract to AmerisourceBergen Drug Corporation's Corporate Office division to provide Ocrevus 300 mg/10 ml vials. The fixed-price contract, valued at $69,354.24, has a completion date of June 6, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued up to $999,999,999.00 through December 31, 2025. The IDC serves as the primary vehicle for...
- The Defense Logistics Agency (DLA) awarded a firm fixed price delivery order to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, to provide OCREVUS 300 MG/10 ML VIAL 10ML. The $135,712.32 contract has a completion date of March 30, 2023. Amerisourcebergen Drug Corp, a for-profit organization, has received numerous previous awards from DLA to supply pharmaceuticals and medical supplies in support of military treatment programs and facilities. This delivery order is...
- The U.S. government has awarded a Delivery Order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of the pharmaceutical product OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a Firm Fixed Price pricing type and a ceiling value of $23,118.08. The contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a civilian agency that provides logistics and acquisition services to the U.S. Department of Defense....
- This federal contract award, issued by the Defense Logistics Agency (DLA), provides for the delivery of OCREVUS 300 mg/10 ml vials to the government. The contract was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, in the amount of $23,118.08. The contract is a Firm Fixed Price Delivery Order, with a completion date of May 31, 2024. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide 4,564,042,504 units of the pharmaceutical product OCREVUS 300 MG/10 ML VIAL 10ML. The contract has a ceiling value of $115,590.40 and a period of performance through April 11, 2024. AmerisourceBergen Drug Corp is the prime contractor and the parent company Cencora, Inc. is the parent vendor. This...
- The U.S. Defense Logistics Agency Troop Support Medical has awarded a $115,590.40 firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, for the supply of OCREVUS 300 MG/10 ML VIAL 10ML. This delivery order is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp by DLA, with a potential value of $999,999,999.00 and a performance period through December 31, 2025. The IDC serves as the...